158. 結節性硬化症 Tuberous sclerosis Clinical trials / Disease details

臨床試験数 : 112 / 薬物数 : 71 - (DrugBank : 19) / 標的遺伝子数 : 35 - 標的パスウェイ数 : 118

diseases per page:

Showing 1 to 10 of 112 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05252585 (ClinicalTrials.gov)	April 23, 2023	16/2/2022	A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous Sclerosis ...	Phase IV, Prospective Single Arm Study of Safety and Efficacy of Votubia (Everolimus) in Taiwanese A ...	Renal Angiomyolipoma	Drug: Everolimus	Novartis Pharmaceuticals	NULL	Not yet recruiting	20 Years	65 Years	All	10	Phase 4	NULL
2	NCT05495425 (ClinicalTrials.gov)	June 1, 2022	4/8/2022	Clinical Study of NPC-12Y Gel in Patients With Skin Lesions Associated With TSC	Placebo-controlled Comparative Study of NPC-12Y Gel in Patients With Skin Lesions Associated With Tu ...	Tuberous Sclerosis Complex	Drug: NPC-12Y gel;Drug: NPC-12Y placebo gel	Nobelpharma	NULL	Recruiting	3 Years	N/A	All	40	Phase 3	Japan
3	NCT05604170 (ClinicalTrials.gov)	May 16, 2022	5/10/2022	Open-label Study of Adjunctive GNX Treatment in Children and Adults With TSC-related Epilepsy	A Phase 3, Open-label Study of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults With Tub ...	Tuberous Sclerosis Complex	Drug: Ganaxolone	Marinus Pharmaceuticals	NULL	Enrolling by invitation	1 Year	65 Years	All	169	Phase 3	United States
4	NCT05323734 (ClinicalTrials.gov)	April 1, 2022	21/3/2022	Adjunctive GNX Treatment Compared With Placebo in Children and Adults With TSC-related Epilepsy	A Phase 3, Double-blind, Randomized, Placebo-controlled Trial of Adjunctive Ganaxolone (GNX) Treatme ...	Tuberous Sclerosis Complex	Drug: Ganaxalone;Drug: Placebo	Marinus Pharmaceuticals	NULL	Recruiting	1 Year	65 Years	All	162	Phase 3	United States;Canada;France;Germany;Israel;Italy;Spain;United Kingdom
5	ChiCTR2200055795	2022-02-01	2022-01-20	Effect of ultrapulse carbon dioxide laser combined with photodynamic therapy on facial angiofibroma ...	Effect of ultrapulse carbon dioxide laser combined with photodynamic therapy on facial angiofibroma ...	tuberous sclerosis complex	Treatment Group:ultrapulse carbon dioxide laser combined with photodynamic therapy;	The First Hospital of Hebei Medical University	NULL	Pending	6	60	Both	Treatment Group:5;		China
6	NCT05104983 (ClinicalTrials.gov)	October 13, 2021	22/10/2021	Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study	Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study	Tuberous Sclerosis Complex;Epilepsy	Drug: Sirolimus;Drug: Placebo	Darcy Krueger	NULL	Recruiting	1 Day	6 Months	All	64	Phase 2	United States
7	NCT05044819 (ClinicalTrials.gov)	July 7, 2021	30/8/2021	Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol ...	A Long-term Safety Study to Assess the Potential for Chronic Liver Injury in Participants Treated Wi ...	Lennox Gastaut Syndrome;Dravet Syndrome;Tuberous Sclerosis Complex	Drug: Cannabidiol	Jazz Pharmaceuticals	NULL	Recruiting	1 Year	N/A	All	150	Phase 4	United States
8	NCT04485104 (ClinicalTrials.gov)	May 19, 2021	21/7/2020	Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis ...	An Open-label, Single-arm Study to Assess the Safety, Pharmacokinetics, and Efficacy of Adjunctive C ...	Seizure in Participants With Tuberous Sclerosis Complex;Seizure in Participants With Dravet Syndrome ...	Drug: GWP42003-P	Jazz Pharmaceuticals	NULL	Recruiting	1 Month	23 Months	All	27	Phase 3	United States
9	NCT04987463 (ClinicalTrials.gov)	May 7, 2021	28/5/2021	Efficacy and Safety of Rapamycin Versus Vigabatrin in the Prevention of Tuberous Sclerosis ComplexSy ...	Randomized, Placebo-controlled, Double-blind and Double-dummy Clinical Trial Comparing the Safety, T ...	Tuberous Sclerosis Complex	Drug: Vigabatrin;Drug: Rapamycin;Drug: Placebo	Katarzyna Kotulska	NULL	Recruiting	4 Weeks	16 Weeks	All	60	Phase 2/Phase 3	Poland
10	NCT05059327 (ClinicalTrials.gov)	March 3, 2021	20/8/2021	Basimglurant in Children, Adolescents, and Young Adults With TSC	A Phase 2B, Multicenter, 30-week, Prospective, Cross-over, Double-blind, Randomized, Placebo-control ...	Tuberous Sclerosis Complex	Drug: Basimglurant with crossover to Placebo;Drug: Placebo with crossover to Basimglurant	Noema Pharma AG	NULL	Recruiting	5 Years	30 Years	All	54	Phase 2	United States;Australia;India;Israel;Italy;Poland;Spain;Turkey;United Kingdom

First Previous1 2 3 4 5…12Next Last